Advanced search
Publication Cover
OncoImmunology Volume 2, 2013 - Issue 12
Submit an article Journal homepage
783
Views
8
CrossRef citations to date
0
Altmetric
Author's View

TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity

Marc Cartellieri Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany
,
Claudia Arndt Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany
,
Anja Feldmann Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany; Institute of Radiopharmaceutical Cancer Research; Helmholtz-Zentrum Dresden-Rossendorf; Dresden, Germany
,
Malte von Bonin Medical Clinic and Polyclinic I; University Hospital ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany
,
Eva-Maria Ewen Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany
,
Stefanie Koristka Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany
,
Irene Michalk Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany
,
Slava Stamova Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany
,
Nicole Berndt Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany
,
Anne Gocht Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany
,
Martin Bornhäuser Medical Clinic and Polyclinic I; University Hospital ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany
,
Gerhard Ehninger Medical Clinic and Polyclinic I; University Hospital ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany
,
Marc Schmitz Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany; Center for Regenerative Therapies Dresden; TU Dresden; Dresden, Germany
&
Michael Bachmann Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany; Institute of Radiopharmaceutical Cancer Research; Helmholtz-Zentrum Dresden-Rossendorf; Dresden, Germany; Center for Regenerative Therapies Dresden; TU Dresden; Dresden, GermanyCorrespondence[email protected]
 show all
Article: e26770 | Received 07 Oct 2013, Accepted 10 Oct 2013, Published online: 22 Oct 2013

References

  • Arndt C, von Bonin M, Cartellieri M, Feldmann A, Koristka S, Michalk I, Stamova S, Bornhäuser M, Schmitz M, Ehninger G, et al. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia 2013; 27:964 - 7; http://dx.doi.org/10.1038/leu.2013.18; PMID: 23325142
  • Feldmann A, Arndt C, Töpfer K, Stamova S, Krone F, Cartellieri M, Koristka S, Michalk I, Lindemann D, Schmitz M, et al. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J Immunol 2012; 189:3249 - 59; http://dx.doi.org/10.4049/jimmunol.1200341; PMID: 22875801
  • Stamova S, Cartellieri M, Feldmann A, Bippes CC, Bartsch H, Wehner R, Schmitz M, von Bonin M, Bornhäuser M, Ehninger G, et al. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia 2011; 25:1053 - 6; http://dx.doi.org/10.1038/leu.2011.42; PMID: 21415850
  • Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974 - 7; http://dx.doi.org/10.1126/science.1158545; PMID: 18703743
  • Stamova S, Cartellieri M, Feldmann A, Arndt C, Koristka S, Bartsch H, Bippes CC, Wehner R, Schmitz M, von Bonin M, et al. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. Mol Immunol 2011; 49:474 - 82; http://dx.doi.org/10.1016/j.molimm.2011.09.019; PMID: 22014687
  • Arndt C, Feldmann A, von Bonin M, Cartellieri M, Ewen EM, Koristka S, Michalk I, Stamova S, Berndt N, Gocht A, et al. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia 2013; 10; http://dx.doi.org/10.1038/leu.2013.243; PMID: 23958923
  • Koristka S, Cartellieri M, Arndt C, Bippes CC, Feldmann A, Michalk I, Wiefel K, Stamova S, Schmitz M, Ehninger G, et al. Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. J Autoimmun 2013; 42:105 - 16; http://dx.doi.org/10.1016/j.jaut.2013.01.002; PMID: 23352111
  • Hornig N, Kermer V, Frey K, Diebolder P, Kontermann RE, Müller D. Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. J Immunother 2012; 35:418 - 29; http://dx.doi.org/10.1097/CJI.0b013e3182594387; PMID: 22576347
  • Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, Temme A, Schmitz M. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol 2010; 2010:956304; http://dx.doi.org/10.1155/2010/956304; PMID: 20467460
  • Davila ML, Brentjens R, Wang X, Rivière I, Sadelain M. How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology 2012; 1:1577 - 83; http://dx.doi.org/10.4161/onci.22524; PMID: 23264903

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.